NeoGenomics, Inc. Hits New 52-Week High of $17.45

NeoGenomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 17.45 on August 26, 2026. This achievement marks a notable increase from its 52-week low of USD 6.65, reflecting a robust performance over the past year with a gain of 30.41%. In comparison, the S&P 500 has shown a performance of 18.71% during the same period. With a market capitalization of USD 933 million, NeoGenomics operates in a competitive industry where it has established its presence despite facing challenges typical of loss-making entities, as indicated by its negative return on equity of -8.39%. The company's price-to-book ratio stands at 1.12, suggesting a valuation that may attract attention in the market. Additionally, NeoGenomics maintains a low debt-to-equity ratio of 0.22, indicating a conservative approach to leveraging. As the company continues to navigate the dynamic landscape of pharmaceuticals and biotechnology, its recent stock performance underscores its current market position and operational developments.